Published in Medical Letter on the CDC and FDA, December 7th, 2008
"We have continued to make significant progress since providing our second quarter 2008 update. In August, we initiated a Phase 1 study in normal healthy volunteers of RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, and recently reported positive preliminary results from that trial, including a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA